Professor Richard Scolyer, a world-renowned melanoma pathologist, died Monday, June 8, 2026, at age 59 [1].

Scolyer was a leading figure in oncology whose work significantly advanced the treatment of skin cancer. His death marks the loss of a scientist who transitioned from treating patients to becoming a public symbol of resilience and medical innovation in Australia.

The professor died following a three-year struggle with inoperable brain cancer [2]. He was diagnosed with the tumor in 2023 [1]. Despite undergoing experimental immunotherapy treatment, the condition proved fatal [1].

Scolyer gained national prominence beyond the laboratory, serving as the Australian of the Year in 2024 [3]. His career focused on melanoma pathology, where he sought to improve outcomes for patients facing aggressive cancers.

Throughout his illness, Scolyer remained a public figure, often discussing his journey and the application of medical research to his own case. He said he was "a proud everyday Aussie who gave it a crack" [4].

He encouraged others to pursue their dreams and passion with humility, love, and compassion [5]. His contributions to cancer research provided a foundation for many current immunotherapy protocols used globally.

Colleagues and public health officials said Scolyer's visibility during his treatment brought attention to the complexities of brain cancer and the urgent need for further funding in neuro-oncology research.

“a proud everyday Aussie who gave it a crack”

The death of Professor Richard Scolyer underscores the current limitations of immunotherapy in treating certain inoperable brain tumors. Despite his status as a top expert in the field and access to experimental treatments, the outcome highlights a critical gap in oncology—the transition from successful melanoma treatments to effective brain cancer therapies.